Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals's GHG Emissions Data Preview
In 2023, Alnylam Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Alnylam Pharmaceuticals has also provided a category-level breakdown for 3 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Alnylam Pharmaceuticals's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals amounted to 13,442 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals decreased by 5.3%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Alnylam Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Alnylam Pharmaceuticals's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Alnylam Pharmaceuticals were 3,529 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Alnylam Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 1 emissions have increased by 15.55%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Alnylam Pharmaceuticals's Scope 1 emissions decreased by 13.46%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Alnylam Pharmaceuticals's Scope 2 emissions?
In 2023, Alnylam Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 9,933 tCOâ‚‚e using the market-based method, and 9,913 tCOâ‚‚e using the location-based method.
Has Alnylam Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 16.38%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Alnylam Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Alnylam Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Alnylam Pharmaceuticals use for Scope 2 reporting?
In 2023, Alnylam Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.
Alnylam Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Alnylam Pharmaceuticals's Value Chain Emissions
In 2023, Alnylam Pharmaceuticals reported 6,937 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Alnylam Pharmaceuticals includes a breakdown across 3 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Alnylam Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Alnylam Pharmaceuticals's Scope 3 emissions?
In 2023, Alnylam Pharmaceuticals reported total Scope 3 emissions of 6,937 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Alnylam Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 3 emissions have increased by 126.4%, reflecting a rising long-term trend in Scope 3 emissions over time.
Compared to the previous year (2022), Alnylam Pharmaceuticals's Scope 3 emissions increased by 18.52%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Alnylam Pharmaceuticals disclose?
In 2023, Alnylam Pharmaceuticals reported emissions for 3 out of the 15 Scope 3 categories defined by the GHG Protocol.
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Alnylam Pharmaceuticals's Scope 3 emissions?
In 2023, the largest contributors to Alnylam Pharmaceuticals's Scope 3 emissions were:
- Business Travel (Cat. 6): 3,270 tCOâ‚‚e (47.14%)
- Employee Commuting (Cat. 7): 2,560 tCOâ‚‚e (36.9%)
- Waste Generated in Operations (Cat. 5): 1,107 tCOâ‚‚e (15.96%)
Alnylam Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Alnylam Pharmaceuticals's Total Carbon Footprint
In 2023, Alnylam Pharmaceuticals reported a total carbon footprint of 20,379 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 1.66% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Alnylam Pharmaceuticals's total carbon footprint was Scope 2 emissions, accounting for 48.64% of the company's total carbon footprint, followed by Scope 3 emissions at 34.04%.